Broadening Treatment for Patients with Newly Diagnosed NSCLC
Speakers: Julie Brahmer, Co-director, Upper Aerodigestive DepartmentHossein Borghaei, DO, MS
Duration: 60 minutes
Presented on: December 4, 2023
Co-director, Upper Aerodigestive Department
Hossein Borghaei, DO, MS
Hossein Borghaei, DO, MS
Updating Providers on New Strategies in the Targeted Landscape for NSCLC
LEARNING OBJECTIVESAfter completing this activity, the participant should be better able to:
Jointly provided by Postgraduate Institute for Medicine and PlatformQ Health Education, LLC
- Identify the best treatment options based on patient diagnosis and testing
- Discuss the importance of companion diagnostics and re‐biopsy to test for
- secondary mutations and ensure the proper therapeutic plan
- Review the guidelines and goals for targeted therapy for EGFR+ and ALK+/ROS1+NSCLC
- Assess the current and emerging EGFR, ALK/ROS inhibitors for targeted therapy
Supported by an educational grant from Eli Lilly and Takeda Pharmaceuticals U.S.A., Inc.
JOINT ACCREDITATION STATEMENTIn support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and PlatformQ Health Education, LLC. Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
ENDURING CREDIT DESIGNATION STATEMENTThe Postgraduate Institute for Medicine designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
DATE OF RELEASE/EXPIRATION
Enduring MaterialJuly 15, 2021 – July 15, 2022.
TARGET AUDIENCEThe intended audience for this activity program are medical oncologists, thoracic oncologists, pulmonologists, nurse practitioners, physician assistants, nurses, and other members on the NSCLC treatment team.
ESTIMATED TIME TO COMPLETEThis activity should take approximately 1 hour to complete.
METHOD OF PARTICIPATIONThere are no fees to participate in this activity. To participate in the activity, go to www.OMedLive.com. To receive credit, participants must (1) read the target audience, learning objectives, and disclosure statements, (2) complete the educational activity online, and (3) complete the post-test and activity evaluation. To receive AMA PRA Category 1 Credit™, participants must receive a minimum score of 70% on the post-test.
HARDWARE/SOFTWARE REQUIREMENTSParticipants will need a computer with a recent version of Adobe Flash installed, as well as an internet connection sufficient for streaming media.
DISCLOSURE OF CONFLICTS OF INTERESTPostgraduate Institute for Medicine (PIM) requires instructors, planners, managers and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.
The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:
Name of Faculty or Presenter Reported Financial Relationship Gilberto de Lima Lopes Junior, MD, MBA, FASCO
Professor of Clinical Medicine
Medical Director for International Programs
Associate Director for Global Oncology
Interim Chief, Division of Medical Oncology
Sylvester Comprehensive Cancer Center at the University of Miami and the Miller School of Medicine
Consultant/Independent Contractor: AstraZeneca and Pfizer
Grant/Research Support: Abbvie, Adaptimmune Therapeutics, AstraZeneca, Bavarian Nordic, Blueprint Medicines, Bristol Myers Squibb, Eli Lilly, EMD Serono, E.R. Squibb Sons, LLC, GlaxoSmithKline, Genentech, G1 Therapeutics, Janssen, Lucence, Merck Sharp & Dohme, Novartis, Pfizer, Rgenix, Roche, Tesaro, Xilis
Advisory Board: AstraZeneca and Pfizer
Honoraria: Boehringer Ingelheim
Travel, Accommodations, Expenses: Boehringer Ingelheim, Celgene, E.R. Squibb Sons, LLC, Janssen, Pfizer, Seattle Genetics
The planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:
Name of Faculty or Presenter Reported Financial Relationship Tariqa Ackbarali
PlatformQ Health Education, LLC
The PIM planners and managers have nothing to disclose.
The following PlatformQ Health Education, LLC planner, Bridget Griffin, hereby states that she or her spouse/life partner do not have any financial relationships or relationships to products or devices with any commercial interest related to the content of this activity of any amount during the past 12 months.
DISCLOSURE OF UNAPPROVED/OFF LABEL USE (if applicable):This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
DISCLAIMER:Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
CONTACT INFORMATIONAccreditation Support: Please contact the Postgraduate Institute for Medicine at firstname.lastname@example.org.
Technical Support: For any technical issues or issues with your CME Certificate, please contact OMedLive at 877-394-1306 or at Support@OMedLive.com.